Soluble Urokinase Receptor Levels in Plasma during 5 Years of Highly Active Antiretroviral Therapy in HIV-1-Infected Patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 4, 2004, Pages 337-342

  Ostrowski, Sisse R ^a   Katzenstein, Terese L ^a   Piironen, Timo ^b   Gerstoft, Jan ^a   Pedersen, Bente K ^a   Ullum, Henrik ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

HAART; HIV 1 infection; Immune activation; Inflammation; STNFr; SuPAR

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2; SOLUBLE UROKINASE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MORTALITY; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; VIRAL LOAD;

EID: 1542618423     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200404010-00002     Document Type: Article

References (15)

1. Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96: 4091-4095.
2. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15:398-408.
3. Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis Proteolysis. 1998;12:191-204.
4. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
5. Juffermans NP, Dekkers PE, Verbon A, et al. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun. 2001;69:5182-5185.
6. Eugen-Olsen J, Gustafson P, Sidenius N, et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis. 2002;6:686-692.
7. Slot O, Brunner N, Locht H, et al. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis. 1999; 58:488-492.
8. Wada M, Wada NA, Shirono H, et al. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Commun. 2001;284:346-351.
9. Handley MA, Steigbigel RT, Morrison SA. A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. J Virol. 1996;70:4451-4456.
10. Katzenstein TL, Ullum H, Roge BT, et al. Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months. HIV Med. 2003;4:53-61.
11. Riisbro R, Christensen IJ, Piironen T, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res. 2002;8:1132-1141.
12. Riisbro R, Piironen T, Brünner N, et al. Measurements of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand and Assay. 2002; 25:53-56.
13. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179: 74-82.
14. Stein DS, Lyles RH, Graham NM, et al. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study. J Infect Dis. 1997; 176: 1161-1167.
15. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infections. Ann NY Acad Sci. 1988;546:164-174.